Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Oct;29(5):640-643.
doi: 10.1007/s13365-023-01167-7. Epub 2023 Aug 30.

Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C

Affiliations
Case Reports

Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C

Filomena Boccia et al. J Neurovirol. 2023 Oct.

Abstract

About 40% of the Guillain-Barré syndrome (GBS) cases are associated with prodromal infections; occasionally, it has been associated to chronic hepatitis C or its reactivation. A 38-year-old man came to our attention after transaminase elevation occurred during recovery from GBS. All the possible causes of acute hepatitis were excluded except for the positivity of HCVRNA, and a diagnosis of new onset hepatitis C was made. Recalling patient history, we observed that (i) anti-HCV antibodies were negative and liver enzymes were normal 7 weeks before GBS onset; (ii) in the early stages of ICU admission, liver enzymes started to rise, but the elevation remained mild under steroid treatment; (iii) serum aminotransferase peak occurred 11 weeks after GBS onset; and (iv) HCV RNA was already significantly high when anti-HCV antibodies became positive, consistent with an acute hepatitis. Furthermore, anti-HCV seroconversion was likely delayed or blurred by steroids and immunoglobulin infusions. The interval of time between GBS onset and transaminase elevation compared with the patient clinical history allows us to establish a cause-effect relationship between the two diseases. All patients with GBS should be tested for hepatitis C, or its reactivation if already present, and followed up for an early diagnosis and treatment.

Keywords: Diagnosis; Paralysis; Post-viral syndrome; Serology; Viremia.

PubMed Disclaimer

Conflict of interest statement

EDM reports research funding for his Institution from MSD, Pfizer, Angelini, Infectopharm, Advanz pharma, and personal fees or fees to participate in advisory boards or speaker’s honoraria from Roche, Genentech, Pfizer, MSD, Angelini, Advanz pharma, Bio-Merieux, Shionogi, Menarini, Abbvie, Sanofi-Aventis, Medtronic, Trx, and DiaSorin. None of these competing interests affected the present study. FB, RZ, and LLF declare no conflict of interests.

Figures

Fig. 1
Fig. 1
Clinical course of HCV infection over time

Similar articles

Cited by

References

    1. Balwani M, Bawankule C, Ramteke V, Hepatitis Pasari A, C, virus directly acting antivirals and Guillain-Barré syndrome. Saudi J Kidney Dis Transpl. 2018;29(5):1237–1239. doi: 10.4103/1319-2442.243969. - DOI - PubMed
    1. Belbézier A, Bosseray A, Colombe B, Leroy V, Leclercq P, Bouillet L. Guillain-Barré syndrome in AIDS patient secondary to an acute and confirmed hepatitis C virus. Presse Med. 2019;48(9):981–982. doi: 10.1016/j.lpm.2019.08.004. - DOI - PubMed
    1. Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021;384(11):1038–1052. doi: 10.1056/NEJMra2033539. - DOI - PubMed
    1. Chlilek A, Roger C, Muller L, Carles MJ, Stephan R, Laureillard D, Lavigne JP, Lefrant JY, Sotto A. Severe Guillain-Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report. BMC Infect Dis. 2019;19(1):636. doi: 10.1186/s12879-019-4278-7.PMID:31315560;PMCID:PMC6637463. - DOI - PMC - PubMed
    1. De Klippel N, Hautekeete ML, De Keyser J, Ebinger G. Guillain-Barré syndrome as the presenting manifestation of hepatitis C infection. Neurology. 1993;43(10):2143. doi: 10.1212/wnl.43.10.2143. - DOI - PubMed

Publication types